Search

Your search keyword '"Ferella, Letizia"' showing total 19 results
Start Over Author "Ferella, Letizia"
19 results on '"Ferella, Letizia"'

1. Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study

Author

Bresolin, Andrea, Faiella, Adriana, Garibaldi, Elisabetta, Munoz, Fernando, Cante, Domenico, Vavassori, Vittorio, Waskiewicz, Justina Magdalena, Girelli, Giuseppe, Avuzzi, Barbara, Villa, Elisa, Magli, Alessandro, Noris Chiorda, Barbara, Gatti, Marco, Ferella, Letizia, Maggio, Angelo, Landoni, Valeria, Aimonetto, Stefania, Sini, Carla, Rancati, Tiziana, Sanguineti, Giuseppe, Valdagni, Riccardo, Di Muzio, Nadia, Fiorino, Claudio, and Cozzarini, Cesare

Published
2021
Full Text
View/download PDF

2. Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Author

Munoz, Fernando, Fiorica, Francesco, Caravatta, Luciana, Rosa, Consuelo, Ferella, Letizia, Boldrini, Luca, Fionda, Bruno, Alitto, Anna Rita, Nardangeli, Alessia, Dionisi, Francesco, Arcangeli, Stefano, Di Marzo, Alessandro, Pontoriero, Antonio, Donato, Vittorio, and Massaccesi, Mariangela

Published
2021
Full Text
View/download PDF

4. Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis

Author

Ferella, Letizia, Limoncin, Erika, Vittorini, Francesca, Chalaszczyk, Agnieszka, Sorce, Claudia, Grimaldi, Gianmarco, Franzese, Pietro, Ruggieri, Valeria, Varrassi, Emilia, Di Staso, Mario, Gimenez De Lorenzo, Ramon, Marampon, Francesco, Tombolini, Vincenzo, Masciocchi, Carlo, and Gravina, Giovanni Luca

Published
2019
Full Text
View/download PDF

6. Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation

Author

Cozzarini, Cesare, primary, Olivieri, Michela, additional, Magli, Alessandro, additional, Cante, Domenico, additional, Noris Chiorda, Barbara, additional, Munoz, Fernando, additional, Faiella, Adriana, additional, Olivetta, Elisa, additional, Deantoni, Chiara, additional, Fodor, Andrei, additional, Signor, Marco Andrea, additional, Petrucci, Edoardo, additional, Avuzzi, Barbara, additional, Ferella, Letizia, additional, Pastorino, Alice, additional, Garibaldi, Elisabetta, additional, Gatti, Marco, additional, Rago, Luciana, additional, Statuto, Teodora, additional, Rancati, Tiziana, additional, Briganti, Alberto, additional, Montorsi, Francesco, additional, Valdagni, Riccardo, additional, Sanguineti, Giuseppe, additional, Di Muzio, Nadia Gisella, additional, and Fiorino, Claudio, additional

Published
2022
Full Text
View/download PDF

7. Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma

Author

Marampon, Francesco, Leoni, Flavio, Mancini, Andrea, Pietrantoni, Ilaria, Codenotti, Silvia, Ferella, Letizia, Megiorni, Francesca, Porro, Giuliana, Galbiati, Elisabetta, Pozzi, Pietro, Mascagni, Paolo, Budillon, Alfredo, Maggio, Roberto, Tombolini, Vincenzo, Fanzani, Alessandro, Gravina, Giovanni Luca, and Festuccia, Claudio

Published
2019
Full Text
View/download PDF

8. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

Author

Deneuve, Sophie, primary, Bastogne, Thierry, additional, Duclos, Mirlande, additional, Mirjolet, Céline, additional, Bois, Pascaline, additional, Bachmann, Patrick, additional, Nokovitch, Lara, additional, Roux, Pierre-Eric, additional, Girodet, Didier, additional, Poupart, Marc, additional, Zrounba, Philippe, additional, Claude, Line, additional, Ferella, Letizia, additional, Iacovelli, Nicola Alessandro, additional, Foray, Nicolas, additional, Rancati, Tiziana, additional, and Pereira, Sandrine, additional

Published
2022
Full Text
View/download PDF

9. sj-docx-1-tmj-10.1177_03008916221078061 – Supplemental material for Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

Author

Deneuve, Sophie, Bastogne, Thierry, Duclos, Mirlande, Mirjolet, Céline, Bois, Pascaline, Bachmann, Patrick, Nokovitch, Lara, Roux, Pierre-Eric, Girodet, Didier, Poupart, Marc, Zrounba, Philippe, Claude, Line, Ferella, Letizia, Iacovelli, Nicola Alessandro, Foray, Nicolas, Rancati, Tiziana, and Pereira, Sandrine

Subjects
Medicine
Abstract

Supplemental material, sj-docx-1-tmj-10.1177_03008916221078061 for Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study by Sophie Deneuve, Thierry Bastogne, Mirlande Duclos, Céline Mirjolet, Pascaline Bois, Patrick Bachmann, Lara Nokovitch, Pierre-Eric Roux, Didier Girodet, Marc Poupart, Philippe Zrounba, Line Claude, Letizia Ferella, Nicola Alessandro Iacovelli, Nicolas Foray, Tiziana Rancati and Sandrine Pereira in Tumori Journal

Published
2022
Full Text
View/download PDF

10. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

Author

Deneuve, Sophie, Bastogne, Thierry, Duclos, Mirlande, Mirjolet, Céline, Bois, Pascaline, Bachmann, Patrick, Nokovitch, Lara, Roux, Pierre-Eric, Girodet, Didier, Poupart, Marc, Zrounba, Philippe, Claude, Line, Ferella, Letizia, Iacovelli, Nicola Alessandro, Foray, Nicolas, Rancati, Tiziana, and Pereira, Sandrine

Abstract

Objective: Radiotherapy (RT) against head and neck squamous cell carcinomas (HNSCC) may lead to severe toxicity in 30-40% of patients. The normal tissue complication probability (NTCP) models, based on dosimetric data refined the normal tissue dose/volume tolerance guidelines. In parallel, the radiation-induced nucleoshuttling (RIANS) of the Ataxia-Telangiectasia Mutated protein (pATM) is a predictive approach of individual intrinsic radiosensitivity. Here, we combined NTCP with RADIODTECT©, a blood assay derived from the RIANS model, to predict RT toxicity in HNSCC patients.Methods: RADIODTECT© cutoff values (i.e. 57.8 ng/mL for grade⩾2 toxicity and 46 ng/mL for grade⩾3 toxicity) have been previously assessed. Validation was performed on a prospective cohort of 36 HNSCC patients treated with postoperative RT. Toxicity was graded with the Common Terminology Criteria for Adverse Events (CTCAE) scale and two criteria were considered: grade⩾2 oral mucositis (OM2), grade⩾3 mucositis (OM3) and grade⩾2 dysphagia (DY2), grade⩾3 dysphagia (DY3). pATM quantification was assessed in lymphocytes of HNSCC patients. The discrimination power of the pATM assay was evaluated through the Area Under the Receiver Operator Characteristics Curve (AUC-ROC). Two previously described NTCP models were considered, including the dose to the oral cavity and the mean dose to the parotid glands (OM2 and OM3) and the dose to the oral cavity, to the larynx and the volume of pharyngeal constrictor muscles (DY2 and DY3).Results: Combining NTCP models with RADIODTECT© blood test improved the AUC-ROC. Considering the prediction of mucositis, AUC-ROCNTCP+RADIODTECT©=0.80 was for OM2, and AUC-ROCNTCP+RADIODTECT©=0.78 for OM3. Considering the prediction of acute dysphagia, AUC-ROCNTCP+RADIODTECT©=0.71 for DY2 and for DY3.Conclusions: Combining NTCP models with a radiosensitivity biomarker might significantly improve the prediction of toxicities for HNSCC patients.

Published
2023
Full Text
View/download PDF

12. Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy

Author

Ferella, Letizia, primary, Cavallo, Anna, additional, Miceli, Rosalba, additional, Iacovelli, Nicola Alessandro, additional, Giandini, Tommaso, additional, Pignoli, Emanuele, additional, Calareso, Giuseppina, additional, Bossi, Paolo, additional, Resteghini, Carlo, additional, Gravina, Giovanni Luca, additional, Nicolai, Piero, additional, Castelnuovo, Paolo, additional, Piazza, Cesare, additional, Licitra, Lisa, additional, Fallai, Carlo, additional, and Orlandi, Ester, additional

Published
2019
Full Text
View/download PDF

13. Long‐term outcome of re‐irradiation for recurrent or second primary head and neck cancer: A multi‐institutional study of AIRO—Head and Neck working group

Author

Orlandi, Ester, primary, Bonomo, Pierluigi, additional, Ferella, Letizia, additional, D'Angelo, Elisa, additional, Maddalo, Marta, additional, Alterio, Daniela, additional, Infante, Gabriele, additional, Bacigalupo, Almalina, additional, Argenone, Angela, additional, Iacovelli, Nicola Alessandro, additional, Desideri, Isacco, additional, Meduri, Bruno, additional, Triggiani, Luca, additional, Volpe, Stefania, additional, Belgioia, Liliana, additional, Dionisi, Francesco, additional, Romanello, Domenico Attilio, additional, Fallai, Carlo, additional, and Miceli, Rosalba, additional

Published
2019
Full Text
View/download PDF

15. Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).

Author

Alfieri, Salvatore, primary, Ferrara, Roberto, additional, Calareso, Giuseppina, additional, Cavalieri, Stefano, additional, Platini, Francesca, additional, Mancinelli, Moela, additional, Resteghini, Carlo, additional, Orlandi, Ester, additional, Iacovelli, Nicola Alessandro, additional, Ferella, Letizia, additional, Piazza, Cesare, additional, Apollonio, Giulia, additional, Galbiati, Donata, additional, Bossi, Paolo, additional, Bergamini, Cristiana, additional, Locati, Laura Deborah, additional, and Licitra, Lisa F., additional

Published
2019
Full Text
View/download PDF

16. Prevalence of Fatigue in Head and Neck Cancer Survivors

Author

Bossi, Paolo, primary, Di Pede, Patricia, additional, Guglielmo, Mauro, additional, Granata, Roberta, additional, Alfieri, Salvatore, additional, Iacovelli, Nicola Alessandro, additional, Orlandi, Ester, additional, Guzzo, Marco, additional, Bianchi, Roberto, additional, Ferella, Letizia, additional, Infante, Gabriele, additional, Miceli, Rosalba, additional, Licitra, Lisa, additional, and Ripamonti, Carla Ida, additional

Published
2019
Full Text
View/download PDF

17. Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy

Author

Ferella, Letizia, Cavallo, Anna, Miceli, Rosalba, Iacovelli, Nicola Alessandro, Giandini, Tommaso, Pignoli, Emanuele, Calareso, Giuseppina, Bossi, Paolo, Resteghini, Carlo, Gravina, Giovanni Luca, Nicolai, Piero, Castelnuovo, Paolo, Piazza, Cesare, Licitra, Lisa, Fallai, Carlo, and Orlandi, Ester

Abstract

Background: We evaluated the prognostic role of gross tumor volumes (GTVs) of primary tumor and positive lymph nodes on overall survival (OS) and progression-free survival (PFS) in locally advanced unresectable sinonasal cancer (SNC) treated with definitive intensity-modulated radiotherapy (IMRT) with or without chemotherapy.Methods: Primary tumor GTV (GTV-T), pathologic neck nodes GTV (GTV-N), and positive retropharyngeal nodes GTV (GTV-RPN) of 34 patients with epithelial nonglandular SNC receiving IMRT with or without chemotherapy were retrospectively measured. The GTV variables were analyzed in relation with OS and PFS. Survival curves were estimated using the Kaplan-Meier method and compared with the log-rank test. We also estimated the crude cumulative incidence of locoregional relapses only. The optimal volume cutoff value was determined using an outcome-oriented method among the observed values.Results: GTV-T was significantly associated with decreased OS (P=0.003) and PFS (P=0.003). Moreover, patients with disease total volumes (GTV) smaller than 149.44 cm³ had better OS and PFS than patients with higher volumes (P<0.0001 for both). Neck nodal metastasis impacted on OS and PFS (P=0.030 and P=0.033, respectively), but GTV-N did not (P=0.961; P=0.958). Retropharyngeal nodes metastasis was not associated with prognosis (OS: P=0.400; PFS: P=0.104). When GTV-RPN was added to GTV-N (GTV-TN), a relation with PFS (P=0.041) and a trend toward significance for OS (P=0.075) were found.Conclusions: Our results show that tumor volume is a powerful predictor of outcome in SNC. This could be useful to identify patients with worse prognosis deserving different treatment strategies.

Published
2020
Full Text
View/download PDF

18. Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Author

Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S, Ferella L, Megiorni F, Porro G, Galbiati E, Pozzi P, Mascagni P, Budillon A, Maggio R, Tombolini V, Fanzani A, Gravina GL, and Festuccia C

Subjects
Animals, Apoptosis, Cell Movement, Cell Proliferation, Cell Transformation, Neoplastic metabolism, Cell Transformation, Neoplastic pathology, Glioblastoma metabolism, Glioblastoma pathology, Humans, In Vitro Techniques, Male, Mice, Mice, Nude, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Phenotype, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Carbamates pharmacology, Cell Transformation, Neoplastic drug effects, Glioblastoma drug therapy, Histone Deacetylases chemistry, Neoplastic Stem Cells drug effects
Abstract

Purpose: Aberrant expression and activity of histone deacetylases (HDACs) sustain glioblastoma (GBM) onset and progression, and, therefore, HDAC inhibitors (HDACi) represent a promising class of anti-tumor agents. Here, we analyzed the effects of ITF2357 (givinostat), a pan-HDACi, in GBM models for its anti-neoplastic potential., Methods: A set of GBM- and patient-derived GBM stem-cell lines was used and the ITF2357 effects on GBM oncophenotype were investigated in in vitro and in vivo xenograft models., Results: ITF2357 inhibited HDAC activity and affected GBM cellular fate in a dose-dependent manner by inducing G 1 /S growth arrest (1-2.5 µM) or caspase-mediated cell death (≥ 2.5 µM). Chronic treatment with low doses (≤ 1 µM) induced autophagy-mediated cell death, neuronal-like phenotype, and the expression of differentiation markers, such as glial fibrillar actin protein (GFAP) and neuron-specific class III beta-tubulin (Tuj-1); this reduces neurosphere formation from patient-derived GBM stem cells. Autophagy inhibition counteracted the ITF2357-induced expression of differentiation markers in p53-expressing GBM cells. Finally, in in vivo experiments, ITF2357 efficiently passed the blood-brain barrier, so rapidly reaching high concentration in the brain tissues, and significantly affected U87MG and U251MG growth in orthotopic xenotransplanted mice., Conclusions: The present findings provide evidence of the key role played by HDACs in sustaining transformed and stem phenotype of GBM and strongly suggest that ITF2357 may have a clinical potential for the HDACi-based therapeutic strategies against GBM.

Published
2019
Full Text
View/download PDF

19. Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes.

Author

Valeriani M, Bonfili P, Reverberi C, Marinelli L, Ferella L, Minniti G, DE Sanctis V, Osti MF, Bonome P, Tronnolone L, Varrassi E, Gravina GL, Franzese P, Tombolini V, and DI Staso M

Subjects
Aged, Aged, 80 and over, Follow-Up Studies, Gastrointestinal Diseases etiology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prostatic Neoplasms pathology, Radiation Dose Hypofractionation, Radiotherapy, Image-Guided adverse effects, Risk Factors, Time Factors, Treatment Outcome, Prostatic Neoplasms radiotherapy, Radiotherapy, Image-Guided methods
Abstract

Background/aim: To evaluate outcomes in patients with low-risk prostate cancer treated with hypofractionated radiotherapy (HyRT)., Patients and Methods: Between April 2004 and December 2015, 175 patients with low-risk prostate cancer were treated with HyRT 60 Gy in 20 fractions with or without image guidance and reduction of margin from clinical target volume to planning target volume., Results: The median follow-up was 66 months. The 8-year overall survival for the whole patient cohort was 88.9%. The 8-year biochemical no evidence of disease was higher in patients treated with image-guided HyRT (98.8% vs. 88%, p=0.023). During treatment, patients treated with image-guided HyRT presented a lower rate of grade 1-2 gastrointestinal toxicity (25.3% vs. 42.2%, p=0.001). At the last follow-up, the grade 1 Gastro-intestinal toxicity rate was 4.0% and the grade 1-2 genito-urinary toxicity rate was 25.1%., Conclusion: Our study demonstrated the efficacy of the schedule used with a low rate of acute and late toxicities. Therefore, reduction of margins with image-guided HyRT is safe., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results